New designs for studies of the prophylaxis of bipolar disorder

Journal of Clinical Psychopharmacology

Volumn 22, Issue 1, 2002, Pages 1-3

  Post, Robert M ^a   Keck Jr , Paul ^a   Rush, A John ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMOTRIGINE; LITHIUM; PLACEBO; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID;

AREA UNDER THE CURVE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG APPROVAL; EDITORIAL; FOOD AND DRUG ADMINISTRATION; MANIC DEPRESSIVE PSYCHOSIS; MEDICAL ETHICS; MOOD; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REMISSION;

ANTIMANIC AGENTS; BIPOLAR DISORDER; HUMANS; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 0036154796     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200202000-00001     Document Type: Editorial

References (24)

1. NIMH workshop report on treatment of bipolar disorder
2. National Institute of Mental Health workshop report on the treatment of bipolar disorder
3. The Stanley Foundation Bipolar Network. Part I: Rationale and methods
4. The Stanley Foundation Bipolar Treatment Outcome Network: I. Longitudinal methodology
5. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder
6. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder
7. New clinical research findings in bipolar disorder
8. A 25-year-old woman with bipolar disorder
9. The evaluation of different approaches to randomized clinical trials. Report on the 1987 MacArthur Foundation Network I Methodology Workshop
10. Design of clinical trials
11. Design issues for the clinical evaluation of psychotropic drugs
12. Decision processes in establishing the efficacy and safety of psychotropic agents
13. Special issues in trial design and use of placebo in bipolar illness
14. Statistical approaches to trial durations in episodic affective illness
15. To increase power in randomized clinical trials without increasing sample size
16. Methodological issues in developing new acute treatments for patients with bipolar illness
17. Maintenance clinical trials in bipolar disorder: Design implications of the divalproexlithium-placebo study
18. Mood stabilizers and the evolution of maintenance study designs in bipolar I disorder
19. Placebo control groups in randomized treatment trials: A statistician's perspective
20. Flexible treatment strategies in chronic disease: Clinical and research implications
21. Evaluating pharmacologic treatments for bipolar disorder
22. Improvement of phase III psychotropic drug trials by intensive phase II work
23. Perspectives for clinical research on bipolar disorders in the new millennium
24. Are randomised controlled trials the only gold that glitters?